2014
Systemic Treatment and Radiation Necrosis Following Gamma Knife Radiosurgery in the Treatment of Brain Metastases
Colaco R, Martin P, Bond J, Bindra R, Contessa J, Kluger H, Yu J, Chiang V. Systemic Treatment and Radiation Necrosis Following Gamma Knife Radiosurgery in the Treatment of Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s310. DOI: 10.1016/j.ijrobp.2014.05.1035.Peer-Reviewed Original Research
2013
Ipilimumab-induced Perforating Colitis
Mitchell KA, Kluger H, Sznol M, Hartman DJ. Ipilimumab-induced Perforating Colitis. Journal Of Clinical Gastroenterology 2013, 47: 781-785. PMID: 23632354, PMCID: PMC6091636, DOI: 10.1097/mcg.0b013e31828f1d51.Peer-Reviewed Original ResearchConceptsIpilimumab-induced colitisSteroid therapyHistologic findingsT-lymphocyte-associated antigen 4Common side effectsAssociated histologic findingsBowel perforationSubtotal colectomyMucosal biopsiesSegmental resectionStandard treatmentAntigen-4Metastatic melanomaColitisSide effectsMonoclonal antibodiesTherapyIpilimumabColectomyDiarrheaPatientsPerforationTreatmentResectionBiopsy
2012
Drug targets and predictive biomarkers in the management of metastatic melanoma
Thumar J, Giesen E, Kluger HM. Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmacogenomics And Personalized Medicine 2012, Volume 5: 139-148. PMID: 23226069, PMCID: PMC3513235, DOI: 10.2147/pgpm.s25100.Peer-Reviewed Original ResearchMetastatic melanomaPredictive biomarkersApproval of ipilimumabChoice of treatmentImmune system characteristicsFederal Drug AdministrationClinical benefitTherapeutic optionsFatal skin cancerTreatment strategiesDrug combinationsMelanoma treatmentPromising drugAntitumor effectsDrug AdministrationSkin cancerIndividual tumorsMelanomaPersonalized therapyTherapyTreatmentDrug targetsBiomarkersIpilimumabTumorsImmunotherapy for metastatic melanoma
Zito CR, Kluger HM. Immunotherapy for metastatic melanoma. Journal Of Cellular Biochemistry 2012, 113: 725-734. PMID: 22006439, DOI: 10.1002/jcb.23402.Peer-Reviewed Original ResearchConceptsMetastatic melanomaPromising investigational approachesTreatment of melanomaImmunogenic tumorsAntitumor immunityCTLA-4Interleukin-2First cytokineInvestigational approachesProlonged responseMelanomaMonoclonal antibodiesImmunotherapyTreatmentIpilimumabPatientsCytokinesTumorsSmall subsetDiseaseImmunityAntibodies